Rocket Pharmaceuticals, Inc. (RCKT) Total liabilities 2016–2025
Rocket Pharmaceuticals, Inc. (RCKT) total liabilities at each fiscal year-end, per SEC filings.
$53.2MFY2025 · since FY2016: $56.5M → $53.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $53.2M | -17.4% |
| FY2024 | $64.5M | -12.6% |
| FY2023 | $73.8M | +18.7% |
| FY2022 | $62.1M | +46.9% |
| FY2021 | $42.3M | -51.6% |
| FY2020 | $87.3M | +34.7% |
| FY2019 | $64.8M | +13.2% |
| FY2018 | $57.3M | +1137.6% |
| FY2017 | $4.6M | -91.8% |
| FY2016 | $56.5M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More RCKT financial trends
RCKT RevenueRCKT Net incomeRCKT Net marginRCKT Gross profitRCKT Gross marginRCKT Operating incomeRCKT Operating marginRCKT Operating cash flowRCKT Free cash flowRCKT Capital expendituresRCKT Return on equityRCKT Stock buybacksRCKT Dividends paidRCKT Total assetsRCKT Shareholders’ equityRCKT overview →